a Unit of Infectious Diseases, Department of Medicine, Huddinge , Karolinska Institutet , Stockholm , Sweden.
b Department of Infectious Diseases, Danderyds Hospital , Stockholm , Sweden.
Infect Dis (Lond). 2018 Nov-Dec;50(11-12):807-816. doi: 10.1080/23744235.2018.1486511. Epub 2018 Oct 26.
The aim of this observational cohort study was to determine the incidence and risk factors of active tuberculosis (TB) in persons living with HIV in a low endemic setting over a 17-year time period when combination antiretroviral therapy (ART) has been available. We thereby aimed to understand the usefulness of TB chemoprophylaxis among HIV patients with latent TB.
All 2127 adult patients diagnosed with HIV January 1996-December 2013 at the Karolinska University Hospital in Stockholm County were eligible. After exclusion of 259 patients transferred to other clinics, 1868 were followed until TB diagnosis, death or end of study period (December 2013). The median follow-up time was 7.9 years (interquartile range, 3.9-11.5).
Active TB was diagnosed in 92 patients, corresponding to an incidence rate of 6.2 cases (95% CI 5.1-7.6) per 1000 person-years with a significant decline over time. The majority (52%) of TB cases were diagnosed within 1 month from HIV diagnosis. Being a migrant from a TB-endemic region, was the only patient characteristic associated with significantly higher risk of active TB (Hazard Ration, HR: 8.54, 95% confidence interval, CI: 3.09-23.61 in a multivariate regression analysis controlling for route of HIV transmission, year of HIV diagnosis and CD4-cell count and viral load at HIV diagnosis. The number needed to treat to prevent one case of TB among patients in this high-risk group was 22 (95% CI 26-47).
The incidence of active TB in persons living with HIV in Stockholm County declined significantly after the introduction of ART but was still 80 times higher than in the general population at the end of the study period. The therapeutic gain of chemoprophylaxis in low endemic settings should be weighed against costs and side effects.
本观察性队列研究旨在确定在抗逆转录病毒疗法(ART)普及的 17 年间,在低流行地区,HIV 感染者中活动性结核病(TB)的发病率和危险因素。因此,我们旨在了解潜伏性结核 HIV 患者中 TB 化学预防的有效性。
所有于 1996 年 1 月至 2013 年 12 月期间在斯德哥尔摩县卡罗林斯卡大学医院诊断出的 2127 名成年 HIV 感染者都符合条件。排除转至其他诊所的 259 名患者后,有 1868 名患者接受了随访,直至诊断出 TB、死亡或研究期结束(2013 年 12 月)。中位随访时间为 7.9 年(四分位距,3.9-11.5)。
诊断出 92 例活动性 TB,发病率为 6.2 例(95%CI5.1-7.6)/1000 人年,且呈时间性显著下降。大多数(52%)TB 病例在 HIV 诊断后 1 个月内诊断出。来自结核病流行地区的移民是唯一与活动性 TB 风险显著增加相关的患者特征(在多变量回归分析中,校正 HIV 传播途径、HIV 诊断年份、HIV 诊断时的 CD4 细胞计数和病毒载量后,风险比为 8.54,95%CI3.09-23.61)。在该高危人群中,预防 1 例 TB 所需的治疗人数为 22 人(95%CI26-47)。
斯德哥尔摩县 HIV 感染者中活动性 TB 的发病率在 ART 引入后显著下降,但在研究期末仍比一般人群高 80 倍。在低流行地区,化学预防的治疗效益应与成本和副作用相权衡。